FDA Approves 1st Immunotherapy Breast Cancer Drug The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) received accelerated approval for triple-negative breast cancer that is locally advanced or has spread, cannot be surgically removed, and has cells that have a protein called PD-L1, CNN reported.
|
2026. Szeptember 15. Enikő, Melitta napja van
